GlassScriptPhysician profile
Sandra T Yeh
NPI 1366477606
$9,618.25
in general payments reported to CMS, 2019-2025
31 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $1,257 · 2021: $1,707 · 2022: $1,460 · 2023: $1,234 · 2024: $1,210 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,649 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,649.11 |
| Education | $271.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,944.24 | 2019-2025 | Dupixent |
| Abbvie INC. | $1,248.56 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $893.34 | 2019-2025 | |
| Pfizer INC. | $824.39 | 2019-2025 | |
| Leo Pharma INC. | $769.01 | 2019-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $495.59 | 2019-2021 | |
| Galderma Laboratories, L.P. | $440.38 | 2019-2025 | Nemluvio |
| Vyne Pharmaceuticals INC. | $378.61 | 2020-2021 | |
| Incyte Corporation | $358.78 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $297.33 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $288.76 | 2019-2021 | |
| Janssen Biotech, INC. | $272.59 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Epi Health, LLC | $268.33 | 2019-2021 | |
| Journey Medical Corporation | $172.09 | 2019-2025 | |
| Amgen INC. | $169.62 | 2019-2023 | Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $149.72 | 2019-2025 | |
| Dermavant Sciences, INC. | $128.59 | 2022-2024 | Vtama |
| Almirall LLC | $95.89 | 2019-2021 | |
| Organon LLC | $69.49 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $67.24 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $47.64 | 2023-2024 | Zoryve |
| Astellas Pharma US INC | $31.72 | 2025 | Izervay |
| Lilly USA, LLC | $31.38 | 2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $29.64 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $24.08 | 2019 | |
| Biofrontera INC. | $22.97 | 2019-2020 | |
| Mission Pharmacal Company | $22.95 | 2019 | |
| Genentech USA, INC. | $21.88 | 2022 | |
| Dermira, INC. | $20.09 | 2019 | |
| Promius Pharma LLC | $19.60 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.